Professional Documents
Culture Documents
Tuberculosis (TB) Disease of antiquity Three main types: Site of disease Bacterially confirmed Drug sensitive / resistant
Tuberculosis: 2011
12.0 million people living with TB 8.7 million new cases in the year 1.4 million people died of TB during the year
[WHO- Global TB Control 2012]
Tuberculosis: 2011
South East Asia 40% Western Pacific 20% Africa 26%
Undiagnosed Cases
Diabetes Mellitus 2011 366 M with DM 183 M (50%) undiagnosed Tuberculosis 2011 8.7 M with TB 2.9 M (33%) not-notified to NTPs
Diabetes mellitus
Jeon CY, Murray MB. Diabetes Mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Medicine 2008; 5: e152
Search of PubMed and EMBASE databases: studies reporting age-adjusted quantitative estimate of association between DM and active TB dating back to 1965
RESULTS
1,786,212 participants with 17,698 TB cases
DM associated with increased risk of TB [Cohort studies = RR 3.1, 95% CI 2.3 4.3]
[Case control studies = OR 1.2 7.8]
Higher risks in young people and communities with high background TB incidence
India
[Stevenson et al BMC Public Health 2007]
Epidemiological model constructed based on 21M adults with DM and 900,000 new TB cases in 2000 DM accounted for: 15% PTB : 20% smear-positive PTB Urban areas more affected than rural areas
Diabetes mellitus makes substantial contribution to burden of new TB in India
Some evidence that poor DM control increases TB risk (HbA1c >7% = RR 2.56) [USA,UK, Canada, Mexico, Russia, India, Taiwan, South Korea, Indonesia]
Patients with DM have low levels of IFNgamma, reduced white cell killing activity
ALSO:Diabetes Mellitus associated with: Pulmonary microangiopathy Renal failure Increased risk of TB
Micronutrient Disturbances
The recommendations
1. Bi-directional screening
Screening TB patients for Diabetes (DM) [DM may not be recognised clinically] Screening DM patients for active TB [TB may present differently]
Jeon CY et al, TMIH 2010; 15: 1300-1314
Karnataka 32%
Kerala 44%
Texas 39% Mexico 36% Nigeria 12%
Tanzania 17%
South Pacific ~40%
Implementation of screening
Review of activities and data National Stakeholders Meeting
Screening TB patients for DM in Hospitals and Health Centres in India: data combined for three quarters (Q1-Q3) for 2012
Indicator Number of patients with TB registered over the three quarters Number (%) with known diagnosis of DM Number needing to be screened with RBG TOTAL 8269 682 (8) 7587
7467 (98)
2838 2703 (95) 402 (5) 1084 (13) 1033 (95)
If positive to any one of the symptom checks, this is a positive screen and referral is made to TB services
Screening of Diabetes (DM) Patients for TB in quarter 2, 2012, for all sites combined, India
DM patients Seen in the quarter
Q2-2012 12237
Already diagnosed with TB from elsewhere Screened for TB symptoms in the quarter
Positive TB symptom screen
74 6393 (52%)
135 (2%)
128 (95%)
11 85 80 695
Many questions
Need for better individualised data analysis Co-determinants of TB risk e.g., smoking Cost-efficient screening / diagnostic methods Optimum time to screen TB patients for DM Better data management systems for DM Integration of DM and TB care
Risk of remaining sputum culture positive after 2-3 months of treatment for DM patients with TB versus non-DM patients with TB
DM positive sputum culture 2-3 months/ Total DM Non-DM positive sputum culture 2-3 months/ Total Non-DM
Study
Country
RR (95% CI)
11/71 (15.5%) 32/93 (34.4%) 14/90 (15.6%) 7/41 (17.1%) 8/69 (11.6%)
33/449 (7.3%) 43/301 (14.3%) 16/334 (4.8%) 68/372 (18.3%) 10/68 (14.7%) 13/85 (15.3%) 88/262 (33.6%) 50/163 (30.7%)
2.11 (1.12, 3.98) 2.41 (1.62, 3.57) 3.25 (1.65, 6.40) 0.93 (0.46, 1.90) 0.79 (0.33, 1.88) 2.01 (0.77, 5.24) 2.17 (1.69, 2.78) 0.98 (0.54, 1.77)
Alisjahbana (2007) Indonesia Banu Rekha (2007) India Blanco (2007) Guler (2007)* Dooley (2009)
Canary Islands,Spain 4/13 (30.8%) Turkey USA 32/44 (72.7%) 9/30 (30%)
.3
Country
Japan 3/71 (4.2%) 3/32 (9.4%) 4/50 (8.0%) 1/40 (2.5%) 5/56 (8.9%) 7/50 (14%) 2/40 (5%) 13/22 (59.1%) 8/18 (44.4%) 8/32 (25%) 34/172 (19.8%) 5/20 (25%) 8/44 (18.2%) 8/73 11.0%) 14/449 (3.1%) 29/746 3.9%) 19/773 (2.5%) 43/667 (6.4%) 49/1044 (4.7%) 1/105 (0.95%) 26/852 (3.1%) 29/152 (19.1%) 14/108 (13.0%) 8/100 (8%) 61/409 (14.9%) 87/440 19.8%) 175/1872 (9.3%) 97/1438 (6.7%) 3/383 (0.8%) 0/540 (0%) 86/537 (16.0%) 112/1022 (11%) 6/44 (13.6%) 137/886 (15.5%) 20/255 (7.8%) 0/82 (0%) 11/143 (7.7%)
RR (95% CI)
1.36 (0.40, 4.60) 2.41 (0.78, 7.50) 3.25 (1.15, 9.20) 0.39 (0.05, 2.74) 1.90 (0.79, 4.59) 14.70 (1.86, 116.27) 1.64 (0.40, 6.66) 3.10 (1.92, 4.99) 3.43 (1.68, 6.98) 3.13 (1.28, 7.65) 1.33 (0.91, 1.94) 1.26 (0.58, 2.76) 1.94 (1.02, 3.70) 1.62 (0.82, 3.21) 0.95 (0.10, 9.08) 28.47 (1.38, 588.46) 1.49 (0.99, 2.26) 1.07 (0.78, 1.48) 3.67 (1.23, 10.93) 1.40 (1.05, 1.86) 1.82 (0.78, 4.27) 7.16 (0.35, 146.29) 2.28 (1.08, 4.85) 1.85 (1.50, 2.28)
Ambrosetti (1995 Report) Italy Ambrosetti (1996 Report) Italy Ambrosetti (1997 Report) Italy Centis (1998 Report) Bashar (2001) Centis (1999 Report) Fielder (2002) Oursler (2002) Mboussa (2003) Ponce d Leon (2004) Kourbatova (2006) Mathew (2006) Pina (2006) Singla (2006) Alisjahbana (2007) Vasankari (2007) Fisher-Hoch (2008) Hasibi (2008) Chiang (2009) Dooley (2009) Maalej (2009) Wang (2009) Italy USA Italy USA USA Congo Mexico Russia Russia Spain
Saudi Arabia 1/134 (0.7%) Indonesia Finland USA Iran Taiwan USA Tunisia Taiwan 2/94 (2.1%) 22/92 (23. 9%) 46/391 (11.8%) 3/6 (50.0%) 52/241 (21.6%) 6/42 (14.3%) 2/57 (3.5%) 13/74 (17.6%)
Summary Heterogeneity I-squared = 44% (9, 66) Weights are from random effects analysis .3 1 1.85 7
Study
Country
RR (95% CI)
Wada, 2000
Japan
7/61 (11%)
4/284 (1%)
6/17 (35%)
9/77 (12%)
Singla, 2006
3/367 (1%)
Maalej, 2009
Tunisia
4/55 (7%)
1/82 (1%)
Zhang, 2009
China
33/165 (20%)
9/170 (5%)
Summary
Heterogeneity I-squared = 0% (0,79) Weights are from random effects analysis .3 1 3.89 15 60
Many questions
DM control and TB treatment outcomes 6-months anti-TB treatment adequate? Timing of death in DM-TB patients Reasons for death Strategies to prevent death Recurrent TB reactivation or re-infection? Integration of DM and TB care
3. Preventing TB in DM
Two observational studies in 1958 and 1969 showing that isoniazid prophylaxis in DM patients reduces risk of TB Knowledge gaps:
Very poorly conducted studies and therefore evidence base still weak
Pfaffenberg et al, 1958 [Germany] Lesnichii et al, 1969 [Russia]
Harries AD et al, Int J Tuberc Lung Dis 2011; 15: 1436 - 1444
Framework for collaborative activities exists but needs to be guided by better evidence